Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “RVNC.”
Based in Newark, California, Revance Therapeutics is a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Tyler P. Pender, Josephine Chen and Beth LeBow. The tax team included partner Rachel D. Kleinberg and associate Caroline E. Dayton. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Members of the Davis Polk team are based in the Northern California and New York offices.